New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:31 EDTROSGRosetta Genomics receives final NY approval for its kidney cancer test
Rosetta Genomics announced that the New York State Department of Health has given the company final approval for its Rosetta Kidney Cancer Test for testing on patient samples from the State. Rosetta Genomics has been offering its Kidney Cancer Test in New York under conditional approval since December 9, 2013 and now has full approval in all 50 U.S. states. The Kidney Cancer Test is the company's proprietary microRNA-based assay that can classify the four most common kidney tumors: Clear Cell Renal Cell Carcinoma, Papillary RCC, Chromophobe RCC and Oncocytoma. With this final approval, each of Rosetta's cancer testing services now has full New York State approval.
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
12:28 EDTROSGRosetta Genomics to host business news update conference call
Business News Update Conference call to be held on September 18 at 10 am. Webcast Link
September 3, 2014
08:18 EDTROSGRosetta Genomics initiates post-marketing registry study of Cancer Origin Test
Subscribe for More Information
September 2, 2014
08:21 EDTROSGRosetta Genomics, Moffitt Cancer enter cancer diagnostics alliance
Rosetta Genomics announces that the company has entered into a strategic alliance with Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, to discover, develop and commercialize a variety of microRNA-based cancer diagnostics. Under the three-year alliance Rosetta will provide funding for Moffitt investigator-initiated projects that align with Rosetta's strategic priorities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use